Invention Grant
- Patent Title: Antagonist of the BTLA/HVEM interaction for use in therapy
-
Application No.: US14891501Application Date: 2014-02-21
-
Publication No.: US10005839B2Publication Date: 2018-06-26
- Inventor: Daniel Olive , Christine Pasero , Julie Gertner-Dardenne
- Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Institut Jean Paoli & Irene Calmettes , Universite d'Aix Marseille , Centre National de la Recherche Scientifique—CNRS
- Applicant Address: FR Paris FR Marseille FR Marseille FR Paris
- Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),INSTITUT JEAN PAOLI & IRENE CALMETTES,UNIVERSITE D'AIX-MARSEILLE,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
- Current Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),INSTITUT JEAN PAOLI & IRENE CALMETTES,UNIVERSITE D'AIX-MARSEILLE,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
- Current Assignee Address: FR Paris FR Marseille FR Marseille FR Paris
- Agency: Whitham, Curtis & Cook, P.C.
- Priority: EP13305639 20130517
- International Application: PCT/EP2014/053422 WO 20140221
- International Announcement: WO2014/183885 WO 20141120
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/00
Abstract:
Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of Vγ9Vδ2 T cells.
Public/Granted literature
- US20160090420A1 ANTAGONIST OF THE BTLA/HVEM INTERACTION FOR USE IN THERAPY Public/Granted day:2016-03-31
Information query
